KR102655833B1 - T-세포 전림프구성 백혈병의 치료에 사용하기 위한 티노스타무스틴 - Google Patents

T-세포 전림프구성 백혈병의 치료에 사용하기 위한 티노스타무스틴 Download PDF

Info

Publication number
KR102655833B1
KR102655833B1 KR1020197037098A KR20197037098A KR102655833B1 KR 102655833 B1 KR102655833 B1 KR 102655833B1 KR 1020197037098 A KR1020197037098 A KR 1020197037098A KR 20197037098 A KR20197037098 A KR 20197037098A KR 102655833 B1 KR102655833 B1 KR 102655833B1
Authority
KR
South Korea
Prior art keywords
cells
pll
treatment
tinostamustine
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197037098A
Other languages
English (en)
Korean (ko)
Other versions
KR20200015563A (ko
Inventor
토마스 요르크 메를링
마르코 헤를링
Original Assignee
유로-셀띠끄 소시에떼 아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유로-셀띠끄 소시에떼 아노님 filed Critical 유로-셀띠끄 소시에떼 아노님
Publication of KR20200015563A publication Critical patent/KR20200015563A/ko
Application granted granted Critical
Publication of KR102655833B1 publication Critical patent/KR102655833B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197037098A 2017-06-13 2018-06-13 T-세포 전림프구성 백혈병의 치료에 사용하기 위한 티노스타무스틴 Active KR102655833B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1709402.0 2017-06-13
GBGB1709402.0A GB201709402D0 (en) 2017-06-13 2017-06-13 Compounds for treating t-pll
PCT/EP2018/065664 WO2018229132A1 (en) 2017-06-13 2018-06-13 Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia

Publications (2)

Publication Number Publication Date
KR20200015563A KR20200015563A (ko) 2020-02-12
KR102655833B1 true KR102655833B1 (ko) 2024-04-08

Family

ID=59358363

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197037098A Active KR102655833B1 (ko) 2017-06-13 2018-06-13 T-세포 전림프구성 백혈병의 치료에 사용하기 위한 티노스타무스틴

Country Status (14)

Country Link
US (4) US11318117B2 (https=)
EP (1) EP3638231B1 (https=)
JP (1) JP7195283B2 (https=)
KR (1) KR102655833B1 (https=)
AR (1) AR112101A1 (https=)
AU (1) AU2018285821B2 (https=)
BR (1) BR112019026484A2 (https=)
CA (1) CA3067276A1 (https=)
ES (1) ES2966954T3 (https=)
GB (1) GB201709402D0 (https=)
IL (1) IL271017A (https=)
MX (1) MX392103B (https=)
TW (1) TW201919616A (https=)
WO (1) WO2018229132A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
AU2016426574B2 (en) 2016-10-11 2023-07-13 Euro-Celtique S.A. Hodgkin lymphoma therapy
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
KR20210105380A (ko) * 2018-12-18 2021-08-26 먼디파머 인터내셔널 코포레이션 리미티드 다발성 골수종을 치료하기 위한 화합물
US12186393B2 (en) 2019-08-02 2025-01-07 Onehealthcompany, Inc. Method of treating transitional cell carcinoma in a canine by administering lapatinib, wherein the carcinoma harbors a BRAF mutation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015181154A1 (en) 2014-05-28 2015-12-03 Euro-Celtique S.A Pharmaceutical combination comprising a class iii receptor tyrosine kinase inhibitor and the alkylating histone-deacetylase inhibitor fusion molecule edo-s101 together with its use in the treatment of cancer
WO2015181157A1 (en) 2014-05-28 2015-12-03 Euro-Celtique S.A. Combination comprising a glucocorticoid and edo-s101
WO2015180865A1 (en) 2014-05-28 2015-12-03 Euro-Celtique S.A. Compounds for treating brain cancer

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE34727C (de) Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue Verfahren zur direkten Gewinnung metallischen Bleis
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5882941A (en) 1994-05-04 1999-03-16 Massachusette Institute Of Technology Programmable genotoxic agents and uses therefor
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6133248A (en) 1997-06-13 2000-10-17 Cydex, Inc. Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6214852B1 (en) 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
AU2001273413A1 (en) 2000-07-12 2002-01-21 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1335898B1 (en) 2000-09-29 2005-11-23 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
AU2002243231A1 (en) 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
CN1764648A (zh) 2003-01-13 2006-04-26 安斯泰来制药有限公司 作为组蛋白脱乙酰酶(hdac)抑制剂的异羟肟酸衍生物
JP4790594B2 (ja) 2003-02-25 2011-10-12 トポターゲット ユーケー リミテッド Ｈｄａｃインヒビターとしての、二環式ヘテロアリール基を含むヒドロキサム酸化合物
JP2007501775A (ja) 2003-08-07 2007-02-01 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
CN101010298A (zh) 2004-04-05 2007-08-01 默克Hdac研究有限责任公司 组蛋白脱乙酰酶抑制剂前药
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
ATE542527T1 (de) 2005-05-13 2012-02-15 Topotarget Uk Ltd Pharmazeutische formulierungen von hdac-hemmern
WO2008067027A2 (en) 2006-10-20 2008-06-05 Icos Corporation Compositions of chkl inhibitors and cyclodextrin
GB0621160D0 (en) 2006-10-24 2006-12-06 Imp College Innovations Ltd Compounds and uses thereof
TWI519313B (zh) 2006-11-20 2016-02-01 希佛隆公司 使用放射敏感劑放射敏感化腫瘤之方法
CN101084876A (zh) 2007-07-11 2007-12-12 济南康泉医药科技有限公司 一种含苯达莫司汀的抗癌组合物
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
US20090131367A1 (en) 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
US8987468B2 (en) 2008-02-04 2015-03-24 The Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
CA2735899A1 (en) 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
MX2011003751A (es) 2008-10-08 2011-04-27 Cephalon Inc Procesos para preparar bendamustina.
WO2010075542A1 (en) 2008-12-23 2010-07-01 Curis, Inc. Cdk inhibitors
HRP20150778T1 (hr) 2009-01-23 2015-08-28 Euro-Celtique S.A. Derivati hidroksamske kiseline
ES2525257T3 (es) 2009-02-25 2014-12-19 Supratek Pharma, Inc. Composiciones de ciclopolisacárido y de bendamustina
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
WO2011017448A1 (en) 2009-08-05 2011-02-10 The Trustees Of The University Of Pennsylvania Use of histone deacetylase inhibitors for treatment of autoimmune diseases
CN101928234B (zh) 2010-01-15 2012-12-12 北京欧凯纳斯科技有限公司 6/7-（杂）芳基-n-羟基己/庚酰胺化合物及其制备方法
WO2011130689A1 (en) 2010-04-15 2011-10-20 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
US9889147B2 (en) 2010-04-16 2018-02-13 Cellact Pharma Gmbh Analogues of etoposide for the treatment of tumours
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
US8748470B2 (en) 2011-03-17 2014-06-10 The University Of Chicago Methods for treating ovarian cancer by inhibiting fatty acid binding proteins
JP6330118B2 (ja) 2011-09-13 2018-05-30 ファーマサイクリックス エルエルシー ベンダムスチンと組み合わせたヒストンデアセチラーゼ阻害剤の製剤とその使用
CN102993102B (zh) 2011-09-16 2016-08-24 杭州民生药业有限公司 [1-甲基-2-(7’-庚异羟肟酸基)-5-n，n-二(2’-氯乙基)]-1h-苯并咪唑的合成方法
DK2758052T3 (en) 2011-09-18 2018-05-28 Euro Celtique Sa Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide
RS55680B1 (sr) 2011-09-28 2017-07-31 Euro Celtique Sa Derivati azotnih iperita
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
EP3076963A4 (en) 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
NZ630314A (en) 2014-02-18 2016-03-31 Celgene Corp Combination therapy for hematological malignancies
US9937174B2 (en) 2014-12-05 2018-04-10 University of Modena and Reggio Emilia Combinations of histone deacetylase inhibitors and bendamustine
CN106580971B (zh) 2015-10-20 2019-11-12 杭州梯诺医药科技有限公司 一种药物组合物及其制备方法
AU2016426574B2 (en) 2016-10-11 2023-07-13 Euro-Celtique S.A. Hodgkin lymphoma therapy
US20180098969A1 (en) 2016-10-11 2018-04-12 Purdue Pharmaceutical Products L.P. Hodgkin lymphoma therapy
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
KR20210105380A (ko) 2018-12-18 2021-08-26 먼디파머 인터내셔널 코포레이션 리미티드 다발성 골수종을 치료하기 위한 화합물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015181154A1 (en) 2014-05-28 2015-12-03 Euro-Celtique S.A Pharmaceutical combination comprising a class iii receptor tyrosine kinase inhibitor and the alkylating histone-deacetylase inhibitor fusion molecule edo-s101 together with its use in the treatment of cancer
WO2015181157A1 (en) 2014-05-28 2015-12-03 Euro-Celtique S.A. Combination comprising a glucocorticoid and edo-s101
WO2015180865A1 (en) 2014-05-28 2015-12-03 Euro-Celtique S.A. Compounds for treating brain cancer

Also Published As

Publication number Publication date
ES2966954T3 (es) 2024-04-25
US11918558B2 (en) 2024-03-05
JP2020523359A (ja) 2020-08-06
JP7195283B2 (ja) 2022-12-23
TW201919616A (zh) 2019-06-01
US11318117B2 (en) 2022-05-03
BR112019026484A2 (pt) 2020-07-14
EP3638231B1 (en) 2023-12-20
US20220401417A1 (en) 2022-12-22
AR112101A1 (es) 2019-09-18
MX392103B (es) 2025-03-21
US12370178B2 (en) 2025-07-29
WO2018229132A1 (en) 2018-12-20
IL271017A (en) 2020-01-30
US20260083707A1 (en) 2026-03-26
US20200113871A1 (en) 2020-04-16
EP3638231A1 (en) 2020-04-22
EP3638231C0 (en) 2023-12-20
US20240316009A1 (en) 2024-09-26
AU2018285821B2 (en) 2024-07-04
GB201709402D0 (en) 2017-07-26
KR20200015563A (ko) 2020-02-12
MX2019015208A (es) 2022-05-03
CA3067276A1 (en) 2018-12-20
AU2018285821A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
KR102655833B1 (ko) T-세포 전림프구성 백혈병의 치료에 사용하기 위한 티노스타무스틴
KR101938431B1 (ko) 뇌 종양의 치료를 위한 csf-1r 억제제
BR112019017851A2 (pt) método para tratar câncer em um indivíduo que precisa do mesmo, método para identificar um indivíduo que tem um câncer como um candidato para o tratamento com um antagonista de smarca2, método para identificar uma célula cancerosa como sensível ao tratamento com um antagonista de smarca2, antagonista de smarca2 para uso no tratamento de câncer em um indivíduo que precisa do mesmo, antagonista de smarca2 para uso como um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo e uso do antagonista de smarca2 na fabricação de um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo
KR20200014790A (ko) 난소암의 치료에 사용되는 티노스타무스틴
US12121565B2 (en) Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies
KR20200014789A (ko) Tnbc 치료용 화합물
EP3220908B1 (en) Compositions and methods for treating endometriosis
JP7586835B2 (ja) ミトコンドリア標的化及び抗癌治療のためのアルキルｔｐｐ化合物
KR101401891B1 (ko) 테모졸로미드 및 발프로산을 함께 이용하는 항암적 용도
CN116234543A (zh) 用于用gsh合成抑制剂和抗癌组合物治疗过度增殖性病症的组合物
US20250352555A1 (en) Method of increasing immune cell activation and/or treating cancer using dibenzoxazepinones
US10213449B2 (en) Compositions and methods for treating medulloblastoma
JP2022518143A (ja) ビタミンｅならびにがん治療用組成物および方法
WO2025059216A1 (en) Treatment of high-grade serous carcinoma
US20220273752A1 (en) Modulation of dendritic cell function by the phospholipid messenger lpa
TW201808278A (zh) 二氫異丹蔘酮ｉ於治療癌症之用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191216

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210528

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230829

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240202

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240403

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240404

End annual number: 3

Start annual number: 1

PG1601 Publication of registration